

Robert J Motzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/921299/publications.pdf>

Version: 2024-02-01

467
papers

85,370
citations

807

118
h-index

381

280
g-index

474
all docs

474
docs citations

474
times ranked

39166
citing authors

#	ARTICLE	IF	CITATIONS
1	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 115-124.	13.9	5,409
2	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	13.9	4,889
3	Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2271-2281.	13.9	3,490
4	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
5	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet</i> , The, 2008, 372, 449-456.	6.3	2,848
6	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
7	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.	0.8	2,020
8	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
9	Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 1996, 335, 865-875.	13.9	1,747
10	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1931-1939.	6.3	1,663
11	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	13.9	1,648
12	Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2530-2530.	0.8	1,641
13	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24.	0.8	1,590
14	Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 289-296.	0.8	1,357
15	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	3.8	1,111
16	Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.	2.0	1,039
17	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	13.9	1,004
18	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961

#	ARTICLE	IF	CITATIONS
19	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	13.9	956
20	Systemic Therapy for Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 354-366.	13.9	940
21	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
22	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
23	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
24	Testicular Germ-Cell Cancer. <i>New England Journal of Medicine</i> , 1997, 337, 242-254.	13.9	832
25	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	5.1	789
26	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	6.3	778
27	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482.	5.1	762
28	Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 454-463.	0.8	742
29	A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 63-67.	0.2	677
30	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 552-562.	5.1	640
31	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , 2016, 375, 2246-2254.	13.9	640
32	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
33	SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, 163, 408-417.	0.2	552
34	Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 763-773.	3.0	526
35	A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2005, 173, 48-51.	0.2	480
36	Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-“Clear-Cell Histology. <i>Journal of Clinical Oncology</i> , 2002, 20, 2376-2381.	0.8	459

#	ARTICLE	IF	CITATIONS
37	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834.	2.3	443
38	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncology, The, 2007, 8, 975-984.	5.1	428
39	Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemotherapy and Pharmacology, 2010, 66, 357-371.	1.1	428
40	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. Journal of Clinical Oncology, 2013, 31, 3791-3799.	0.8	388
41	TERATOMA WITH MALIGNANT TRANSFORMATION: DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM CELL TUMORS. Journal of Urology, 1998, 159, 133-138.	0.2	384
42	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
43	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 2765-2772.	0.8	355
44	Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. Journal of Clinical Oncology, 2005, 23, 6549-6555.	0.8	353
45	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	2.0	343
46	Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 5601-5608.	0.8	336
47	Randomized Phase III Trial of Temozolomide Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 760-767.	0.8	331
48	Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. Journal of Clinical Oncology, 2007, 25, 247-256.	0.8	326
49	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3916-3923.	0.8	316
50	Medical Treatment of Advanced Testicular Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 672.	3.8	307
51	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. Clinical Cancer Research, 2013, 19, 3259-3267.	3.2	301
52	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 1432-1439.	0.8	298
53	Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. Journal of Translational Medicine, 2007, 5, 32.	1.8	297
54	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine, 2020, 26, 1733-1741.	15.2	282

#	ARTICLE	IF	CITATIONS
55	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.	0.8	276
56	Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2972-2980.	0.8	267
57	Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. <i>Cancer</i> , 1995, 76, 824-832.	2.0	265
58	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262
59	Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377.	0.8	254
60	Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence. <i>Journal of Clinical Oncology</i> , 2006, 24, 3101-3106.	0.8	251
61	Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. <i>New England Journal of Medicine</i> , 2014, 370, 1769-1770.	13.9	251
62	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 618-630.	2.3	249
63	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
64	Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 71-77.	0.7	244
65	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	5.1	239
66	An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1862-1870.	3.0	231
67	Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2413-2418.	0.8	228
68	Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. <i>Radiology</i> , 2014, 270, 464-471.	3.6	226
69	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
70	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. <i>Clinical Cancer Research</i> , 2015, 21, 1071-1077.	3.2	217
71	Chemotherapy for Teratoma With Malignant Transformation. <i>Journal of Clinical Oncology</i> , 2003, 21, 4285-4291.	0.8	211
72	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	0.9	209

#	ARTICLE	IF	CITATIONS
73	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.	3.2	208
74	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.	5.1	207
75	Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 396-403.	2.5	202
76	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.	2.0	201
77	Tumor Control Outcomes After Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases From Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1744-1748.	0.4	199
78	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971.	0.9	199
79	Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. <i>Oncologist</i> , 2008, 13, 1084-1096.	1.9	198
80	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854.	0.9	198
81	Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159.	2.3	198
82	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003.	5.1	194
83	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.	0.8	192
84	Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 1173-1180.	0.8	187
85	Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 1928-1935.	0.8	187
86	Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 178, 1883-1887.	0.2	186
87	Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 2781-2788.	0.8	185
88	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
89	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1552-1558.	2.0	184
90	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)., 2019, 7, 354.		182

#	ARTICLE	IF	CITATIONS
91	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
92	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019, 75, 100-110.	0.9	178
93	Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3720-3725.	0.8	176
94	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 405-414.	0.9	173
95	Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6302S-6303S.	3.2	169
96	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. <i>Cancer Discovery</i> , 2019, 9, 510-525.	7.7	169
97	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450.	3.2	164
98	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , 2018, 73, 62-68.	0.9	164
99	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	0.8	164
100	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
101	Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 7215-7220.	3.2	159
102	Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , 1997, 157, 860-862.	0.2	157
103	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	3.4	154
104	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	3.2	154
105	Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 24-27.	0.9	148
106	Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.	12.5	148
107	Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 99-101.	1.2	140
108	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	5.8	140

#	ARTICLE	IF	CITATIONS
109	A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 543-546.	1.2	136
110	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298.	1.3	133
111	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369.	0.8	132
112	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	3.4	132
113	Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 873-878.	0.2	131
114	Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. <i>Urology</i> , 2002, 60, 1003-1009.	0.5	128
115	Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310.	2.0	127
116	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.	0.9	125
117	Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3958-3964.	0.8	124
118	Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 3763-3769.	0.8	122
119	Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 491-504.	1.0	122
120	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	0.9	122
121	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 2470-2477.	2.9	121
122	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	5.1	121
123	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481.	2.0	119
124	Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 26, 85-90.	0.8	119
125	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1688-1698.	5.1	119
126	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-772.	0.8	117

#	ARTICLE	IF	CITATIONS
127	Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5597-5602.	0.8	114
128	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.	5.1	114
129	Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 351-358.	1.3	113
130	Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1993, 85, 60-62.	3.0	112
131	mTOR Inhibitors in Advanced Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 835-852.	0.9	112
132	Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 302-306.	0.8	111
133	The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. <i>Cancer Medicine</i> , 2014, 3, 1485-1492.	1.3	110
134	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
135	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.	2.0	109
136	Sunitinib malate for the treatment of solid tumours: a review of current clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 553-561.	1.9	108
137	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529.	0.8	107
138	Renal cell carcinoma. <i>Current Problems in Cancer</i> , 1997, 21, 185-232.	1.0	106
139	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556.	2.0	105
140	RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASION. <i>Journal of Urology</i> , 2005, 174, 557-560.	0.2	103
141	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2016, 17, e4-e5.	5.1	103
142	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 672-693.	2.3	103
143	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
144	Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon- γ 2a for Patients with Advanced Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 257-263.	0.5	102

#	ARTICLE	IF	CITATIONS
145	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
146	Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. <i>Journal of Clinical Oncology</i> , 2001, 19, 682-688.	0.8	99
147	Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037.	0.8	99
148	Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668.	0.8	99
149	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 772-799.	2.3	98
150	Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943.	0.2	97
151	Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 33-39.	2.0	96
152	Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 377-382.	2.1	96
153	Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 2020-2025.	0.8	95
154	Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1312-1319.	0.8	92
155	Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608.	0.8	92
156	Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 9290-9294.	0.8	91
157	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
158	Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 464-467.	0.8	90
159	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 960-977.	2.3	90
160	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
161	Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992, 70, 2354-2357.	2.0	88
162	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	2.9	88

#	ARTICLE	IF	CITATIONS
163	Cytoreductive Nephrectomy " Patient Selection Is Key. <i>New England Journal of Medicine</i> , 2018, 379, 481-482.	13.9	88
164	Treatment outcome for metastatic papillary renal cell carcinoma patients. <i>Cancer</i> , 2006, 107, 2617-2621.	2.0	87
165	Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , 2003, 62, 732-736.	0.5	86
166	Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 107, 1793-1800.	2.0	86
167	Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. <i>International Journal of Surgical Pathology</i> , 2002, 10, 23-32.	0.4	84
168	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	1.9	84
169	Intra- and Interobserver Variability in CT Measurements in Oncology. <i>Radiology</i> , 2013, 269, 451-459.	3.6	83
170	A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 181-189.	1.1	83
171	Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. <i>European Journal of Cancer</i> , 2014, 50, 2162-2170.	1.3	82
172	Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 341-345.	1.2	81
173	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
174	Targeted drugs for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2007, 370, 2071-2073.	6.3	79
175	Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow. <i>Oncologist</i> , 2011, 16, 45-50.	1.9	79
176	Clinical Characteristics and Outcomes of Patients With Recurrence 5 Years After Nephrectomy for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 185, 433-438.	0.2	79
177	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.	1.2	79
178	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
179	Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6999-7004.	0.8	77
180	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76

#	ARTICLE	IF	CITATIONS
181	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 101-101.	0.8	75
182	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275.	3.4	75
183	Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 3995-4000.	0.8	74
184	Phase I clinical trial with fractionated radioimmunotherapy using ¹³¹ I-labeled chimeric G250 in metastatic renal cancer. Journal of Nuclear Medicine, 2004, 45, 1412-21.	2.8	72
185	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-“Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology, 2022, 40, 2333-2341.	0.8	72
186	Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU International, 2006, 97, 933-938.	1.3	71
187	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 502-535.	2.3	71
188	Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer, 1994, 73, 2520-2526.	2.0	70
189	Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. Journal of Urology, 2006, 176, 100-104.	0.2	70
190	Immunohistochemical Expression of Hypoxia Inducible Factor-1 α and its Downstream Molecules in Sarcomatoid Renal Cell Carcinoma. Journal of Urology, 2007, 177, 1258-1263.	0.2	70
191	Sequelae of Treatment in Long-term Survivors of Testis Cancer. European Urology, 2011, 60, 516-526.	0.9	70
192	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 739-750.	1.1	69
193	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-“Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853.	0.8	69
194	Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investigational New Drugs, 2002, 20, 327-330.	1.2	68
195	Targeting Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 3274-3276.	0.8	68
196	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational New Drugs, 2010, 28, 523-528.	1.2	66
197	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669.	2.9	66
198	Partial nephrectomy: The rationale for expanding the indications. Annals of Surgical Oncology, 2002, 9, 680-687.	0.7	64

#	ARTICLE	IF	CITATIONS
199	Chemotherapy for Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 5493-5502.	0.8	64
200	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	0.9	64
201	Phase I Trial of Sunitinib Malate plus Interferon- γ for Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 28-33.	0.9	62
202	Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017, 22, 41-52.	1.9	61
203	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513.	0.8	61
204	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833.	0.9	59
205	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431.	0.8	59
206	Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2003, 170, 1159-1162.	0.2	56
207	Analyzing the Pivotal Trial That Compared Sunitinib and IFN- γ in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth. <i>Clinical Cancer Research</i> , 2012, 18, 2374-2381.	3.2	56
208	Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182.	2.3	56
209	Salvage Chemotherapy for Patients With Advanced Pure Seminoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 297-301.	0.8	54
210	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1176-1178.	2.9	54
211	ALLELIC LOSS ON CHROMOSOMES 8 AND 9 CORRELATES WITH CLINICAL OUTCOME IN LOCALLY ADVANCED CLEAR CELL CARCINOMA OF THE KIDNEY. <i>Journal of Urology</i> , 2002, 167, 1464-1468.	0.2	53
212	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351.	0.9	53
213	Circulating proteins as potential biomarkers of sunitinib and interferon- γ efficacy in treatment-naïve patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 151-161.	1.1	52
214	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	0.9	52
215	Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial. <i>Cancer</i> , 1993, 71, 2515-2521.	2.0	51
216	Long-term follow-up of bilateral sporadic renal tumors. <i>Urology</i> , 2003, 61, 921-925.	0.5	51

#	ARTICLE	IF	CITATIONS
217	Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. <i>BJU International</i> , 2005, 96, 286-290.	1.3	51
218	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 639-646.	0.6	51
219	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.	2.0	50
220	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415.	3.2	50
221	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
222	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.	2.6	50
223	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.2	49
224	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
225	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547.	0.8	49
226	NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-29.	2.3	48
227	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3005-3013.	3.2	48
228	Medullary Renal Cell Carcinoma and Response to Therapy With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, e14-e14.	0.8	47
229	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435.	0.5	47
230	Phase II trial of branched peginterferon- β 2a (40 kDa) for patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1799-1805.	0.6	46
231	Stage migration and increasing proportion of favorable prognosis metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 347-354.	2.0	46
232	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 297-302.	0.9	46
233	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e317-e326.	5.1	46
234	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	5.8	46

#	ARTICLE	IF	CITATIONS
235	Carcinoid tumor of the kidney. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 108-111.	0.8	45
236	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53.	1.7	45
237	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	3.2	45
238	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
239	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 4399-4406.	3.2	44
240	Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. <i>Scientific World Journal, The</i> , 2007, 7, 768-778.	0.8	43
241	Pazopanib versus Sunitinib in Renal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1968-1970.	13.9	43
242	Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649.	2.9	43
243	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	1.6	43
244	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	0.8	43
245	Expression of prostate-specific membrane antigen in renal cortical tumors. <i>Modern Pathology</i> , 2008, 21, 727-732.	2.9	42
246	Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1236-1241.	0.5	42
247	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 107-114.	0.9	42
248	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 292-303.	5.1	42
249	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022.	1.2	41
250	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304.	0.9	41
251	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
252	Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. <i>Cancer</i> , 2003, 98, 1611-1619.	2.0	40

#	ARTICLE	IF	CITATIONS
253	Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. <i>Journal of Urology</i> , 2015, 193, 1911-1917.	0.2	40
254	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
255	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	1.6	40
256	Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2008, 35, 687-701.	0.8	39
257	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
258	Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 12-19.	0.6	39
259	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	0.9	39
260	Innovations and Challenges in Renal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6277S-6281S.	3.2	38
261	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470.	2.0	37
262	Current Algorithms and Prognostic Factors in the Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, S7-S13.	0.9	37
263	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
264	Phase II trial of topotecan in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 143-145.	1.2	36
265	Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2003, 21, 1193-1194.	0.8	36
266	Late relapse of testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 441-445.	0.8	36
267	Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials. <i>Journal of Urology</i> , 2012, 188, 2095-2100.	0.2	35
268	Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 92-95.	1.0	35
269	Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 615-629.	2.3	34
270	Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. <i>Cancer</i> , 2016, 122, 1108-1115.	2.0	34

#	ARTICLE	IF	CITATIONS
271	Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , 2018, 24, 1554-1561.	3.2	34
272	Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. <i>Cancer</i> , 1994, 73, 1892-1894.	2.0	33
273	Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994, 73, 2843-2852.	2.0	33
274	Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007, 99, 993-997.	1.3	33
275	Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012, 118, 5078-5083.	2.0	33
276	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923.	1.7	33
277	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
278	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
279	Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa. <i>Journal of Oncology Practice</i> , 2009, 5, 66-70.	2.5	32
280	Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma. <i>Cell Reports</i> , 2013, 3, 277-281.	2.9	32
281	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.	0.9	32
282	Safety of pazopanib and sunitinib in treatment-naïve patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69.	6.9	32
283	Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression. <i>Cancer Research</i> , 2010, 70, 9682-9692.	0.4	31
284	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
285	Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). <i>Annals of Oncology</i> , 2016, 27, 441-448.	0.6	31
286	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
287	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. <i>European Journal of Cancer</i> , 2018, 94, 87-94.	1.3	31
288	PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 506-514.	3.2	31

#	ARTICLE	IF	CITATIONS
289	all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995, 76, 680-686.	2.0	30
290	Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. <i>BMC Cancer</i> , 2012, 12, 311.	1.1	30
291	Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). <i>BJU International</i> , 2012, 110, 1276-1282.	1.3	30
292	Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. <i>European Urology</i> , 2013, 64, 994-1002.	0.9	30
293	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.	2.0	30
294	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
295	CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 4501-4501.	0.8	30
296	Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003, 62, 1092-1096.	0.5	29
297	New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical Overview. <i>Oncologist</i> , 2011, 16, 1-3.	1.9	29
298	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269.	1.6	29
299	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
300	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
301	A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate) Tj ETQq1 1 0.784314 rgBTD Overlo	1.4	29
302	Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995, 13, 163-165.	1.2	28
303	Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159.	0.5	28
304	Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 328-337.e3.	0.9	28
305	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	1.6	28
306	A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1997, 15, 353-355.	1.2	27

#	ARTICLE	IF	CITATIONS
307	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317.	2.0	26
308	Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 323-325.	1.2	26
309	Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 974-975.	3.0	26
310	Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 614-618.	0.6	26
311	Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Oncologist</i> , 2011, 16, 632-640.	1.9	26
312	Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example. <i>PLoS ONE</i> , 2014, 9, e96316.	1.1	26
313	Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2003, 21, 2679-2688.	0.8	25
314	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.	2.0	25
315	Perspective: What next for treatment?. <i>Nature</i> , 2016, 537, S111-S111.	13.7	25
316	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	0.8	25
317	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17.	0.8	25
318	SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, , 408.	0.2	25
319	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25
320	Cytokine therapy in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 249-257.	0.8	24
321	Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis. <i>Journal of Urology</i> , 2003, 170, 1155-1158.	0.2	24
322	Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 323-338.	2.5	24
323	CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4578-TPS4578.	0.8	24
324	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24

#	ARTICLE	IF	CITATIONS
325	Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2001, 19, 317-320.	1.2	23
326	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173.	3.2	23
327	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.	5.1	23
328	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805.	2.0	22
329	Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 540-547.e7.	0.9	22
330	Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 888-890.	13.9	22
331	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	2.0	22
332	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
333	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.	1.2	21
334	A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 175-182.	1.1	21
335	Phase II Trial of Pegylated Interferon- β 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.	0.9	20
336	Systemic Treatment Options for Untreated Patients With Metastatic Clear Cell Renal Cancer. <i>Seminars in Oncology</i> , 2013, 40, 436-443.	0.8	20
337	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.	0.2	20
338	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	2.6	20
339	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
340	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
341	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
342	Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 383-400.	1.1	20

#	ARTICLE	IF	CITATIONS
343	Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1871-1880.	2.0	19
344	The evolution of anti-angiogenic therapy for kidney cancer. <i>Nature Reviews Nephrology</i> , 2017, 13, 69-70.	4.1	19
345	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10.	1.3	19
346	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
347	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438.	2.3	19
348	Recommendations of follow-up after treatment of germ cell tumors. <i>Seminars in Oncology</i> , 2003, 30, 382-389.	0.8	18
349	Sunitinib therapy in renal cell carcinoma. <i>BJU International</i> , 2008, 101, 1339-1342.	1.3	18
350	Validation and genomic interrogation of the <i>MET</i> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016, 122, 402-410.	2.0	18
351	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518.	0.8	18
352	Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1990, 8, 391-2.	1.2	17
353	Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2008, 26, 273-276.	1.2	17
354	Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234.	1.7	17
355	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	0.8	17
356	Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. <i>Journal of Urology</i> , 2002, 167, 1464-8.	0.2	17
357	Optimal treatment for advanced seminoma?. <i>Cancer</i> , 1993, 72, 3-4.	2.0	16
358	A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576.	0.9	16
359	Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. <i>Medical Oncology</i> , 2011, 28, 1527-1529.	1.2	16
360	High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1093-1105.	1.1	16

#	ARTICLE	IF	CITATIONS
361	Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364.	0.5	16
362	ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993, 20, 111-116.	0.8	16
363	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 1038.	2.3	16
364	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
365	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.2	15
366	Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. <i>European Journal of Cancer</i> , 2016, 59, 57-64.	1.3	15
367	Stage I Testicular Cancer Management and Necessity for Surgical Expertise. <i>Journal of Clinical Oncology</i> , 2008, 26, 2934-2936.	0.8	14
368	Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy. <i>Journal of Clinical Oncology</i> , 2010, 28, 519-521.	0.8	14
369	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372.	0.5	14
370	The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1113-1124.	1.1	14
371	Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868.	3.2	14
372	Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4509-4509.	0.8	14
373	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	0.8	14
374	Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992, 10, 327-330.	1.2	13
375	Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. <i>Urologic Clinics of North America</i> , 2003, 30, 803-817.	0.8	13
376	Calvert's Formula for Dosing Carboplatin: Overview and Concerns of Applicability in High-Dose Setting. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1434-1436.	3.0	12
377	Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. <i>Investigational New Drugs</i> , 2004, 22, 177-179.	1.2	12
378	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.	0.5	12

#	ARTICLE	IF	CITATIONS
379	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	0.5	12
380	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.	0.9	12
381	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
382	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	3.2	12
383	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12
384	A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.	0.8	12
385	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	3.2	12
386	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 6-12.e4.	0.9	11
387	Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 91-93.	13.9	11
388	A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 356-365.e1.	0.9	11
389	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	0.9	11
390	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	0.8	11
391	CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4601-TPS4601.	0.8	11
392	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.	1.6	11
393	A brief symptom index for advanced renal cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 68.	1.0	10
394	Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009, 27, 463-470.	1.2	10
395	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659.	0.5	10
396	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.	0.2	10

#	ARTICLE	IF	CITATIONS
397	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	2.9	10
398	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.	1.1	10
399	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	10
400	Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 299-306.	1.0	9
401	Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. <i>Oncology</i> , 2015, 89, 235-241.	0.9	9
402	Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor–Targeted Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 95-104.	0.8	9
403	830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007, 177, 277-277.	0.2	9
404	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	2.3	9
405	Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , 2006, 20, 1745-53; discussion 1756.	0.4	9
406	Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267.	1.2	8
407	Long-term response with sunitinib for metastatic renal cell carcinoma. <i>Urology</i> , 2006, 68, 672.e19-672.e20.	0.5	8
408	Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. <i>Cancer Medicine</i> , 2014, 3, 1353-1358.	1.3	8
409	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414.	0.9	8
410	Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2016, 90, 119-126.	0.9	8
411	Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 526-533.	0.9	8
412	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021, 39, 313-313.	0.8	8
413	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	1.9	8
414	Adjuvant Chemotherapy for Stage II Nonseminomatous Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2007, 34, 179-185.	0.8	7

#	ARTICLE	IF	CITATIONS
415	Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapyâ€“Kidney Symptom Indexâ€“Disease-Related Symptoms Scale. <i>Value in Health</i> , 2009, 12, 580-586.	0.1	7
416	Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 275-279.	0.8	7
417	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
418	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118.	0.5	7
419	Important Group Differences on the Functional Assessment of Cancer Therapyâ€“Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018, 21, 1413-1418.	0.1	7
420	Comprehensive Genomic Analysis of Metastatic Nonâ€“Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	7
421	Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4503-4503.	0.8	7
422	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	7.7	7
423	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600.	2.0	6
424	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131.	0.5	6
425	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912.	2.9	6
426	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	0.8	6
427	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178.	0.5	6
428	Predicting survival of patients with metastatic renal cell carcinoma. <i>Der Urologe</i> , 2004, 43, 135-136.	2.0	5
429	Editorial: Predicting Necrosis After Chemotherapy for Advanced Nonseminomatous Germ Cell Tumorâ€“Surrogate End Points, Decreasing Morbidity and Patient Outcome. <i>Journal of Urology</i> , 2004, 171, 1842-1843.	0.2	5
430	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084.	0.5	5
431	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.	0.9	5
432	449: The Impact of Residual Extra-Retroperitoneal Masses in Patients with Advanced Non-Seminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2006, 175, 145-146.	0.2	5

#	ARTICLE	IF	CITATIONS
433	Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. <i>Urologic Oncology</i> , 2002, 20, 239-243.	1.5	5
434	A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1998, 16, 337-340.	1.2	4
435	Interferon- γ Resistance Associated Genes in Renal Cell Carcinoma Identified by Expression Profiling. <i>Journal of Urology</i> , 2007, 177, 1264-1268.	0.2	4
436	Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e286-e287.	0.8	4
437	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	1.1	4
438	Partial nephrectomy: The rationale for expanding the indications. , 2002, 9, 680.		4
439	Poor-Risk Testicular Cancer and High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4073-4074.	0.8	3
440	RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. <i>BMC Cancer</i> , 2018, 18, 195.	1.1	3
441	Combination therapy for advanced and metastatic kidney cancer. <i>Nature Reviews Urology</i> , 2019, 16, 77-78.	1.9	3
442	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncol³gica</i> , 2020, 59, 20-27.	0.8	3
443	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.	1.2	3
444	Prognostic Factors for Metastatic Kidney Cancer. <i>Cancer Treatment and Research</i> , 2003, 116, 139-153.	0.2	3
445	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
446	Transcriptional Program Associated with IFN- γ Response of Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 156-170.	0.5	2
447	The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1168-1170.	2.3	2
448	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.2	2
449	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	0.9	2
450	Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2021, 31, 1-9.	0.2	2

#	ARTICLE	IF	CITATIONS
451	Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. , 1995, 76, 824.		2
452	Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. Journal of Clinical Oncology, 2006, 24, 5479-5481.	0.8	1
453	Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. Nature Reviews Urology, 2008, 5, 78-79.	1.4	1
454	Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2010, 28, e740-e740.	0.8	1
455	Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62â€“8. European Urology, 2018, 73, e73.	0.9	1
456	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.3	1
457	Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncology, 2021, 17, 403-409.	1.1	1
458	Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers. , 2017, , .		1
459	Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braudâ€™s Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. Eur Urol 2012;61:826â€“33. European Urology, 2012, 62, e7-e8.	0.9	0
460	From molecular understanding to clinical advances. Nature Reviews Urology, 2014, 11, 77-79.	1.9	0
461	Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.. Journal of Clinical Oncology, 2021, 39, e16542-e16542.	0.8	0
462	IL4 Treatment of Metastatic Renal Cell Carcinoma in 2006 : The Bridge from Yesterday to Tomorrow(IL). Japanese Journal of Urology, 2006, 97, 87.	0.0	0
463	Signal Transduction Inhibitors in Renal Cell Carcinoma. , 2008, , 399-413.		0
464	Sunitinib and Axitinib in Renal Cell Carcinoma. , 2009, , 151-165.		0
465	Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview. , 2009, , 1-12.		0
466	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta OncolÃ³gica, 2022, 61, 52-57.	0.8	0
467	Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2022, 20, .	0.1	0